Bernstein analyst Eve Burstein maintained a Hold rating on Agilent today and set a price target of $125.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eve Burstein’s rating is based on a combination of factors that reflect both positive and negative aspects of Agilent’s recent performance. Agilent demonstrated strong core revenue growth in its 3Q25 results, significantly surpassing both its guidance and market expectations. This growth was consistent across several sectors, indicating a broad recovery in market health. Additionally, management noted an easing in the approval process for capital expenditures, suggesting a more favorable business environment.
However, despite these positive signals, there were some areas of concern that contributed to the Hold rating. Margins were weaker than anticipated, primarily due to increased costs associated with higher revenues, variable pay expectations, and commercial investments. While these factors indicate a positive outlook, they also present challenges that could impact profitability. Furthermore, the stock’s flat performance post-announcement suggests that the market may be overly focused on these negatives, overshadowing the positives. Consequently, Burstein maintains a Hold rating, reflecting a balanced view of the company’s potential and risks.
According to TipRanks, Burstein is a 3-star analyst with an average return of 3.0% and a 54.05% success rate. Burstein covers the Healthcare sector, focusing on stocks such as Waters, Agilent, and Pacific Biosciences.
In another report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $128.00 price target.